TrialClinical and translational science2023

A randomized, controlled trial of prulifloxacin as conversion therapy after intravenous carbapenem in the treatment of acute pyelonephritis caused by third generation cephalosporin resistant pathogens: A pilot study.

Apichot So-Ngern et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.